Molecular Characterization and Disease-Related Morbidities of β-Thalassemia Patients from the Northeastern Part of Iraq

References

• Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704–712.11545326
   PubMed Web of Science ®Google Scholar
• Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev. 2012;26:S12–S15. doi:10.1016/S0268-960X(12)70005-X22631035
   PubMed Web of Science ®Google Scholar
• Rund D. Thalassemia 2016: modern medicine battles an ancient disease. Am J Hematol. 2016;91(1):15–21. doi:10.1002/ajh.2423126537527
   PubMed Web of Science ®Google Scholar
• Nemeth E. Hepcidin in β-thalassemia. Ann N Y Acad Sci. 2010;1202(1):31–35. doi:10.1111/j.1749-6632.2010.05585.x20712769
   PubMed Web of Science ®Google Scholar
• Jalal SD, Al-Allawi NA, Faraj AH, Ahmed NH. Prevalence of haemoglobinopathies in Sulaimani–Iraq. Duhok Med J. 2008;2(1):71–79.
   Google Scholar
• Kadhim KA, Baldawi KH, Lami FH. Prevalence, incidence, trend, and complications of Thalassemia in Iraq. Hemoglobin. 2017;41(3):164–168. doi:10.1080/03630269.2017.135487728836463
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Musallam KM, Cesaretti C, Taher A Thalassemia intermedia. Paper presented at: Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism. Genoa, Italy: Forum Service Editore 2009.
   Google Scholar
• Borgna-Pignatti C, Marsella M, Zanforlin N. The natural history of thalassemia intermedia. Ann N Y Acad Sci. 2010;1202(1):214–220. doi:10.1111/j.1749-6632.2010.05550.x20712795
   PubMed Web of Science ®Google Scholar
• Qatanani M, Taher A, Koussa S, et al. β-Thalassaemia intermedia in Lebanon. Eur J Haematol. 2000;64(4):237–244. doi:10.1034/j.1600-0609.2000.90087.x10776695
   PubMed Web of Science ®Google Scholar
• Najafipour F, Sarisorkhabi R, Bahrami A, et al. Evaluation of endocrine disorders in patients with thalassemia major. Iranian J Endocrinol Metabol. 2008;10(1):35–43.
   Google Scholar
• Taher A, Vichinsky E, Musallam K, Cappellini M-D, Viprakasit V. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation,; 2013.
   Google Scholar
• Baskin HJ, Cobin RH, Duick DS, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocrine Pract. 2002;8(6):457–469. doi:10.4158/1934-2403-8.6.457
   Google Scholar
• Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press; 2001.
   Google Scholar
• Oron-Karni V, Filon D, Oppenheim A, Rund D. Rapid detection of the common mediterranean α-globin deletions/rearrangements using PCR. Am J Hematol. 1998;58(4):306–310.9692395
   PubMed Web of Science ®Google Scholar
• World Health O. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group [‎‎‎meeting held in Rome from 22 to 25 June 1992]‎‎‎. Geneva: World Health Organization; 1994.
   Google Scholar
• Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis Int. 1994;4(6):368–381.
   PubMed Web of Science ®Google Scholar
• Greiner S, Jud A, Aurich M, et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by doppler echocardiography compared to right heart catheterization: analysis in a large patient population. J Am Heart Assoc. 2014;3(4):e001103. doi:10.1161/JAHA.114.00110325146706
   PubMed Web of Science ®Google Scholar
• Al-Allawi NAS, Puehringer H, Raheem RA, Oberkanins C. Genetic modifiers in β-thalassemia intermedia: a study on 102 Iraqi Arab patients. Genet Test Mol Biomarkers. 2015;19(5):242–247. doi:10.1089/gtmb.2014.031025751242
   PubMed Web of Science ®Google Scholar
• Maryami F, Azarkeivan A, Fallah MS, Zeinali S, Large Cohort A. Study of genotype and phenotype correlations of beta- thalassemia in Iranian population. Int J Hematol Oncol Stem Cell Res. 2015;9(4):198–202.26865931
   PubMedGoogle Scholar
• Rahimi Z, Muniz A, Parsian A. Detection of responsible mutations for beta thalassemia in the Kermanshah Province of Iran using PCR-based techniques. Mol Biol Rep. 2010;37(1):149–154. doi:10.1007/s11033-009-9560-019437135
   PubMed Web of Science ®Google Scholar
• Al-Allawi NAS, Jalal SD, Mohammad AM, Omer SQ, Markous RSD. Thalassemia intermedia in Northern Iraq: a single center experience. Biomed Res Int. 2014;2014:9.
   Web of Science ®Google Scholar
• Shamoon RP, Al-Allawi NAS, Cappellini MD, Di Pierro E, Brancaleoni V, Granata F. Molecular basis of β-Thalassemia Intermedia in Erbil Province of Iraqi Kurdistan. Hemoglobin. 2015;39(3):178–183. doi:10.3109/03630269.2015.103241525902180
   PubMed Web of Science ®Google Scholar
• ALTAY Ç, GÜRGEY A. β-Thalassemia Intermedia in Turkey. Ann N Y Acad Sci. 1990;612(1):81–89. doi:10.1111/j.1749-6632.1990.tb24293.x2291577
   PubMedGoogle Scholar
• Elmezayen AD, Kotb SM, Sadek NA, Abdalla EM. β-Globin mutations in Egyptian patients with β-thalassemia. Lab Med. 2015;46(1):8–13. doi:10.1309/LM1AYKG6VE8MLPHG25617386
   PubMed Web of Science ®Google Scholar
• Saud A, Hasan F, Al A, et al. Molecular and biochemical study on β-thalassemia patients in Iraq. Current Res Microbiol Biotechnol. 2014;1:160–165.
   Google Scholar
• Al-Allawi NAS, Hassan KMA, Sheikha AK, Nerweiy FF, Dawood RS, Jubrael J. Thalassemia mutations among transfusion-dependent thalassemia major patients in Northern Iraq. Mol Biol Int. 2010;2010.
   Google Scholar
• Saleh K, Kakey E. Some Molecular Characterization of Βeta-Thalassemia Major in Koya City. 2018.
   Google Scholar
• Omer WA. Molecular characterization of beta-thalassemia mutations in Baghdad. Iraqi J Commun Med. 2010;23(2):90–95.
   Google Scholar
• Adekile AD, Gu LH, Baysal E, et al. Molecular characterization of α-thalassemia determinants, β-thalassemia alleles, and βs haplotypes among Kuwaiti Arabs. Acta Haematol. 1994;92(4):176–181. doi:10.1159/0002042167701914
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Oymak Y, Atabay B, et al. A national registry of thalassemia in Turkey: demographic and disease characteristics of patients, achievements, and challenges in prevention. Turk j Haematol. 2018;35(1):12–18. doi:10.4274/tjh.2017.003928404539
   PubMed Web of Science ®Google Scholar
• Al-Akhras A, Badr M, El-Safy U, et al. Impact of genotype on endocrinal complications in β-thalassemia patients. Biomed Rep. 2016;4(6):728–736. doi:10.3892/br.2016.64627284414
   PubMed Web of Science ®Google Scholar
• Zahed L, Qatanani M, Nabulsi M, Taher A. β-Thalassemia mutations and haplotype analysis in Lebanon. Hemoglobin. 2000;24(4):269–276. doi:10.3109/0363026000899313311186256
   PubMed Web of Science ®Google Scholar
• Rujito L, Sasongko TH. Genetic background of β thalassemia modifier: recent update. J Biomed Transl Res. 2018;4:12–21. doi:10.14710/jbtr.v4i1.2541
   Google Scholar
• Cappellini M-D, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Nicosia, Cyprus: Thalassaemia International Federation; 2014.
   Google Scholar
• Isma’eel H, Shamseddeen W, Taher A, et al. Ventricular late potentials among thalassemia patients. Int J Cardiol. 2009;132(3):453–455. doi:10.1016/j.ijcard.2007.08.10318164497
   PubMed Web of Science ®Google Scholar
• Hashemieh M, Azarkeivan A, Radfar M, et al. Prevalence of osteoporosis among thalassemia patients from zafar adult thalassemia clinic, Iran. Iranian J Blood Cancer. 2014;6(3):143–148.
   Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thrombosis Haemostasis. 2010;8(10):2152–2158. doi:10.1111/j.1538-7836.2010.03940.x
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892. doi:10.1182/blood-2009-09-24315420032507
   PubMed Web of Science ®Google Scholar
• Rafsanjani KA, Mafi N, Tafreshi RI. Complications of β-thalassemia intermedia in Iran During 1996–2010 (Single-Center Study). Pediatr Hematol Oncol. 2011;28(6):497–508. doi:10.3109/08880018.2011.57214421728720
   PubMed Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385. doi:10.1097/01.mph.0000174386.13109.2816012328
   PubMed Web of Science ®Google Scholar
• Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT. Non-transfusion-dependent thalassemia: an update on complications and management. Int J Mol Sci. 2018;19(1):182. doi:10.3390/ijms19010182
   Web of Science ®Google Scholar
• Cappellini MD, Musallam KM, Taher AT. Insight onto the Pathophysiology and Clinical Complications of Thalassemia Intermedia. Hemoglobin. 2009;33(sup1):S145–S159. doi:10.3109/0363026090335152820001620
   PubMedGoogle Scholar
• Skordis N, Sanctis V, Soliman A. Endocrine Disease In: Cappellini CA, Porter J, et al., editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 3rd ed. 2014;147–158. https://www.ncbi.nlm.nih.gov/books/NBK269378/. Accessed 1117, 2020.
   Google Scholar
• Baldini M, Marcon A, Cassin R, et al. Beta-Thalassaemia intermedia: evaluation of endocrine and bone complications. Biomed Res Int. 2014;2014:5. doi:10.1155/2014/174581
   Web of Science ®Google Scholar
• Lai ME, Origa R, Danjou F, et al. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol. 2013;90(6):501–507. doi:10.1111/ejh.1208623414443
   PubMed Web of Science ®Google Scholar
• Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review. Cancer. 2017;123(5):751–758. doi:10.1002/cncr.3046227911488
   PubMed Web of Science ®Google Scholar
• Triantos C, Kourakli A, Kalafateli M, et al. Hepatitis C in patients with β-thalassemia major. A single-centre experience. Ann Hematol. 2013;92(6):739–746. doi:10.1007/s00277-013-1692-623412560
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Rachmilewitz EA. beta-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med. 2012;2(7):a013482. doi:10.1101/cshperspect.a01348222762026
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Motta I. New therapeutic targets in transfusion-dependent and -independent thalassemia. Hematology. 2017;2017(1):278–283. doi:10.1182/asheducation-2017.1.27829222267
   PubMed Web of Science ®Google Scholar
• Derchi G, Galanello R, Bina P, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of B-thalassemia patients using right heart catheterization. Circulation. 2014;129(3):338–345. doi:10.1161/CIRCULATIONAHA.113.00212424081970
   PubMed Web of Science ®Google Scholar
• Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet (London, England). 2018;391(10116):155–167. doi:10.1016/S0140-6736(17)31822-6
   PubMed Web of Science ®Google Scholar
• Al-Allawi NA, Jalal SD, Ahmed NH, Faraj AH, Shalli A, Hamamy H. The first five years of a preventive programme for haemoglobinopathies in Northeastern Iraq. J Med Screen. 2013;20(4):171–176. doi:10.1177/096914131350810524144846
   PubMed Web of Science ®Google Scholar